Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

JVJuliana Vergara-CadavidDana-Farber Cancer InstituteMNMinh NguyenVietnam National University Ho Chi Minh CityBKBrendan KineavyDana-Farber Cancer Institute

Discussion

Loading...

Member takes

Implication

Phase 1 trial evaluated immune response and nk cell behavior in mrd+ multiple myeloma patients receiving melphalan conditioning and asct, indicating enhanced cytotoxicity.

Key Points

  • To characterize the effects of bhv-1100-coated autologous memory-like nk cells in multiple myeloma patients.
  • Conducted a prospective, open-label, single-arm, Phase 1 trial.
  • Evaluated autologous infused nk cells pre-coated with bhv-1100 in patients undergoing asct.
  • Performed immune profiling of peripheral blood and bone marrow via advanced imaging and sequencing techniques.
  • NK cells showed a 100% manufacturing success rate with infusions of 5-10x106 cells/kg-body weight.
  • All patients improved response, achieving MRD- complete response in two at 30 days post-ASCT.
  • Significant expansion of NK cells and alterations in immune markers were noted over time post-infusion.

Cite This Study

Vergara-Cadavid et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd38https://doi.org/10.1182/blood-2025-261
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation2025 · 1 citations
  2. 2Abstract 1322: A cryopreserved allogeneic anti-BCMA CAR-NK cellular therapy exhibits both innate and CAR-mediated MM cell killing <i>in vitro</i> and <i>in vivo</i>2024 · 1 citations
  3. 3Multimodal immunotherapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.2026
  4. 419A phase 0 pilot study of memory-like natural killer (NK) cell immune therapy in patients with renal cell carcinoma or urothelial carcinoma (NCT06318871)2025 · 1 citations
  5. 5Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-10102025 · 24 citations